Last reviewed · How we verify
Corticosteroid 1- C. propionate
Clobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Clobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Severe inflammatory dermatological conditions (e.g., severe psoriasis, lichen planus, severe eczema), Short-term treatment of severe corticosteroid-responsive dermatoses.
At a glance
| Generic name | Corticosteroid 1- C. propionate |
|---|---|
| Also known as | Corticosteroid 1 compared to CP Shampoo |
| Sponsor | Galderma R&D |
| Drug class | Corticosteroid (topical, Class I/super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Clobetasol propionate is a Class I (super-potent) topical corticosteroid that exerts its anti-inflammatory effects through glucocorticoid receptor activation, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. It is used to treat severe inflammatory skin conditions where rapid anti-inflammatory action is required.
Approved indications
- Severe inflammatory dermatological conditions (e.g., severe psoriasis, lichen planus, severe eczema)
- Short-term treatment of severe corticosteroid-responsive dermatoses
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Systemic corticosteroid absorption (with prolonged use or occlusion)
- Local irritation or burning
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid 1- C. propionate CI brief — competitive landscape report
- Corticosteroid 1- C. propionate updates RSS · CI watch RSS
- Galderma R&D portfolio CI